Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214

被引：2
|
作者：
Kivimae, Saul [1 ]
Hennessy, Marlene [1 ]
Pena, Rhoneil [1 ]
Kirksey, Yolanda [1 ]
Nieves, Wildaliz [1 ]
Quatch, Phi [1 ]
Cetz, Janet [1 ]
Ren, Zhongxu [1 ]
Cai, Haiying [1 ]
Deng, BoLiang [1 ]
Zhang, Wen [1 ]
Langowski, John L. [1 ]
Fanton, Christie [1 ]
Anand, Neel K. [1 ]
Rubas, Werner [1 ]
Doberstein, Steve [1 ]
Zalevsky, Jonathan [1 ]
机构：
[1] Nektar Therapeut, San Francisco, CA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3755
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3755
引用
收藏
页数：2
相关论文
共 15 条
  • [1] Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockade
    Langowski, John L.
    Pena, Rhoneil
    Kirksey, Yolanda M.
    Addepalli, Murali K.
    Hoch, Ute
    Zalevsky, Jonathan
    Doberstein, Stephen K.
    Charych, Deborah H.
    CANCER RESEARCH, 2016, 76
  • [2] The CD122-biased immunostimulatory cytokine NKTR-214 combined with checkpoint blockade leads to mobilization of antitumor immunity and synergistic activity
    Langowski, John L.
    Addepalli, Murali
    VanderVeen, Laurie
    Pena, Rhoneil
    Nutakki, Ravikumar
    Kirksey, Yolanda
    Hoch, Ute
    Zalevsky, Jonathan
    Doberstein, Stephen K.
    Charych, Deborah H.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [3] Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).
    Diab, Adi
    Marcondes, Mario
    Kotzin, Brian
    Tagliaferri, Mary Ann
    Hoch, Ute
    Li, Yunfeng
    Cattaruzza, Fiore
    Zalevsky, Jonathan
    Brohl, Andrew Scott
    Brugarolas, James
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Musibay, Evidio Domingo
    Conley, Anthony Paul
    Borazanci, Erkut Hasan
    D'Angelo, Sandra P.
    Curti, Brendan D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [4] NKTR-214 PEGylated engineered interleukin-2 (1L-2) CD122-biased immunostimulatory cytokine Cancer immunotherapy
    Rogers, S. C.
    Shah, H.
    Yin, M.
    Folefac, E.
    Lee, R.
    Verschraegen, C.
    DRUGS OF THE FUTURE, 2018, 43 (05) : 323 - 329
  • [5] REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies
    Diab, A.
    Marcondes, M.
    Tagliaferri, M. A.
    Hoch, U.
    Zhang, J.
    Rubas, W.
    Kivimae, S.
    Zalevsky, J.
    Conley, A. P.
    Borazanci, E.
    D'Angelo, S. P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Antitumor activity of the CD122-biased immunostimulatory cytokine combined with immune checkpoint blockade requires innate and adaptive immunity
    Langowski, John L.
    Kantak, Seema S.
    Pena, Rhoneil
    Kirksey, Yolanda
    Addepalli, Murali
    Lee, Steve
    Hoch, Ute
    Charych, Deborah H.
    Doberstein, Stephen K.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [7] Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG plus RT
    Rolig, Annah S.
    Rose, Daniel C.
    McGee, Grace Helen
    Rubas, Werner
    Kivimae, Saul
    Redmond, William L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [8] Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors.
    Rastelli, Luca
    Gupta, Snigdha
    Jagga, Zeenia
    Charych, Deborah H.
    Zalevsky, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Immune memory in nonclinical models after treatment with NKTR-214, an engineered cytokine biased towards expansion of CD8+T cells in tumor.
    Charych, Deborah H.
    Rubas, Werner
    Dixi, Vidula
    Cetz, Janet
    Pena, Rhoneil
    Langowski, John L.
    Hoch, Ute
    Addepalli, Murali
    Doberstein, Stephen K.
    Zalevsky, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] REVEAL: PHASE 1 DOSE-ESCALATION STUDY OF NKTR-262, A NOVEL TLR7/8 AGONIST, PLUS BEMPEGALDESLEUKIN: LOCAL INNATE IMMUNE ACTIVATION AND SYSTEMIC ADAPTIVE IMMUNE EXPANSION FOR TREATING SOLID TUMORS
    Diab, Adi
    Curti, Brendan
    Bilen, Mehmet
    Brohl, Andrew
    Domingo-Musibay, Evidio
    Borazanci, Erkut
    Fanton, Christie
    Haglund, Cat
    Vimal, Mona
    Muhsin, Mann
    Marcondes, Mario
    Nguyen, Anh
    Tagliaferri, Mary
    Lin, Wei
    Zalevsky, Jonathan
    D'Angelo, Sandra
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A224 - A225
12